Morishita Jintan Initiates Strategic Investments to Meet Diverse Domestic and International Needs
Morishita Jintan Co., Ltd. announces strategic investments to expand its production system, aiming to build a mid-to-long-term growth foundation. This includes adding a new seamless capsule formulation line at the Osaka Technology Center (scheduled for May 2026) and new oil-based liquid formulation manufacturing capabilities at MJ Shiga Co., Ltd. (scheduled for the first half of FY2026).
📋 Article Processing Timeline
- 📰 Published: April 24, 2026 at 19:00
- 🔍 Collected: April 24, 2026 at 10:31
- 🤖 AI Analyzed: April 24, 2026 at 13:24 (2h 52m after Collected)
Morishita Jintan Co., Ltd. (Headquarters: Osaka City; Representative Director and President: Yuji Morishita; Listed on Tokyo Stock Exchange Standard, Securities Code: 4524; hereinafter "the Company") announces that it will sequentially proceed with strategic investments aimed at expanding its production system, with the objective of building a mid-to-long-term growth foundation.
Under its purpose, formulated on the occasion of its 130th anniversary, "With a compassionate heart, with interesting technologies and products, we stay close to each individual, consider all on this planet, and meticulously weave the next health and prosperity," our group develops consumer businesses and solution businesses utilizing its unique technologies. Among these, our "seamless capsule formulation technology," which encapsulates contents with a thin, seamless membrane, is characterized by its ability to form small particles, be multi-layered, and enclose various contents such as liquids and powders in a single capsule. This technology is increasingly being utilized in a wide range of fields, including pharmaceuticals, foods, and cosmetics.
In recent years, against the backdrop of a global rise in health consciousness and the increasing added value of products, the demand for high-quality capsule formulations has been expanding both domestically and internationally. Consequently, the market increasingly emphasizes flexible responsiveness to development and manufacturing needs such as small-lot production, high-mix production, and short delivery times. Furthermore, we believe that possessing manufacturing capabilities for new dosage forms, in addition to seamless capsules and tablets, will lead to strengthening our system to respond more flexibly to market needs.
Based on this market environment, the Company will now implement capital investments in its production bases.
■ Overview of Strategic Investments
1. Osaka Technology Center: Expansion of New Seamless Capsule Formulation Line (Scheduled to operate in May 2026)
To enhance the supply capacity of our flagship product, seamless capsules, we have expanded a new formulation line at the Osaka Technology Center. The introduction of this line will enable flexible response to contract manufacturing for small lots and will also serve as a test line for mass production, leveraging the advantage of being in the same building as the formulation development department. This will support a smooth transition from formulation development to actual production and promote business growth.
2. MJ Shiga Co., Ltd.: Addition of Oil-based Liquid Formulation Manufacturing Function (Scheduled for the first half of FY2026)
At MJ Shiga Co., Ltd. (hereinafter "MJ Shiga"), which joined our group in December 2023, we will establish a new formulation and filling/packaging line for oil-based liquid formulations (such as the "BabyD" series). By adding oil-based liquid formulation manufacturing capabilities to MJ Shiga's one-stop system, which has been cultivated over many years in "tablets" from raw material procurement to final product, we will expand the range of dosage forms that can be produced consistently. This aims to provide more meticulous responses to the diversifying needs of the pharmaceutical and health food markets.
■ Future Outlook
This investment is part of the mid-to-long-term growth strategy promoted by the Company. We will continue to strengthen our production capabilities, including optimizing production processes and further improving our quality control system, and consider continuous capital investments.
By integrating the "spherical technology" developed from the traditional "Jintan" pill-making technology with the knowledge and technology of newly joined group companies, the Company will strive to enhance sustainable corporate value as a company that meets the diverse needs of customers worldwide and delivers "the next health and prosperity."
【Reference: Overview of Morishita Jintan's Production Bases】
● Osaka Technology Center (Osaka Factory):
A base equipped with both development and manufacturing functions, it handles formulation development, product development, filling and packaging of seamless capsules, etc., and the manufacturing of "Jintan." It has established a manufacturing management and quality control system compliant with GMP standards for pharmaceuticals and health foods.
● MJ Shiga Co., Ltd.:
Joined our group in December 2023. A base with advanced tablet manufacturing technology, equipped with a manufacturing management and quality control system compliant with GMP standards for pharmaceuticals and health foods.
● Shiga Factory:
The main production base for seamless capsules. Under strict manufacturing management and quality control compliant with US cGMP standards, it is responsible for manufacturing seamless capsules used in pharmaceuticals, health foods, food products, etc.
Company Name: Morishita Jintan Co., Ltd.
Representative: Yuji Morishita, Representative Director and President
Founded: February 1893 (Meiji 26)
Established: November 1936 (Showa 11)
Main Business: Manufacturing and sales of pharmaceuticals, quasi-drugs, medical devices, and food products.
URL: https://www.jintan.co.jp/
Founder Hiroshi Morishita, with a belief in "service to society," has provided products that contribute to people's health and rich lives since the company's founding in 1893. At that time, it developed as a comprehensive pocket health medicine (then Akadaitsubu Jintan), and later became the silver-coated "Jintan" (currently a quasi-drug, product name: Jintan N) familiar as a refreshing oral agent. Inspired by its manufacturing, it has uniquely developed and expanded its business domain with "seamless capsule technology," and through the accumulation of herbal medicine research and the establishment and cultivation of unique technologies, it conducts corporate activities in a wide range of fields.
Under its purpose, formulated on the occasion of its 130th anniversary, "With a compassionate heart, with interesting technologies and products, we stay close to each individual, consider all on this planet, and meticulously weave the next health and prosperity," our group develops consumer businesses and solution businesses utilizing its unique technologies. Among these, our "seamless capsule formulation technology," which encapsulates contents with a thin, seamless membrane, is characterized by its ability to form small particles, be multi-layered, and enclose various contents such as liquids and powders in a single capsule. This technology is increasingly being utilized in a wide range of fields, including pharmaceuticals, foods, and cosmetics.
In recent years, against the backdrop of a global rise in health consciousness and the increasing added value of products, the demand for high-quality capsule formulations has been expanding both domestically and internationally. Consequently, the market increasingly emphasizes flexible responsiveness to development and manufacturing needs such as small-lot production, high-mix production, and short delivery times. Furthermore, we believe that possessing manufacturing capabilities for new dosage forms, in addition to seamless capsules and tablets, will lead to strengthening our system to respond more flexibly to market needs.
Based on this market environment, the Company will now implement capital investments in its production bases.
■ Overview of Strategic Investments
1. Osaka Technology Center: Expansion of New Seamless Capsule Formulation Line (Scheduled to operate in May 2026)
To enhance the supply capacity of our flagship product, seamless capsules, we have expanded a new formulation line at the Osaka Technology Center. The introduction of this line will enable flexible response to contract manufacturing for small lots and will also serve as a test line for mass production, leveraging the advantage of being in the same building as the formulation development department. This will support a smooth transition from formulation development to actual production and promote business growth.
2. MJ Shiga Co., Ltd.: Addition of Oil-based Liquid Formulation Manufacturing Function (Scheduled for the first half of FY2026)
At MJ Shiga Co., Ltd. (hereinafter "MJ Shiga"), which joined our group in December 2023, we will establish a new formulation and filling/packaging line for oil-based liquid formulations (such as the "BabyD" series). By adding oil-based liquid formulation manufacturing capabilities to MJ Shiga's one-stop system, which has been cultivated over many years in "tablets" from raw material procurement to final product, we will expand the range of dosage forms that can be produced consistently. This aims to provide more meticulous responses to the diversifying needs of the pharmaceutical and health food markets.
■ Future Outlook
This investment is part of the mid-to-long-term growth strategy promoted by the Company. We will continue to strengthen our production capabilities, including optimizing production processes and further improving our quality control system, and consider continuous capital investments.
By integrating the "spherical technology" developed from the traditional "Jintan" pill-making technology with the knowledge and technology of newly joined group companies, the Company will strive to enhance sustainable corporate value as a company that meets the diverse needs of customers worldwide and delivers "the next health and prosperity."
【Reference: Overview of Morishita Jintan's Production Bases】
● Osaka Technology Center (Osaka Factory):
A base equipped with both development and manufacturing functions, it handles formulation development, product development, filling and packaging of seamless capsules, etc., and the manufacturing of "Jintan." It has established a manufacturing management and quality control system compliant with GMP standards for pharmaceuticals and health foods.
● MJ Shiga Co., Ltd.:
Joined our group in December 2023. A base with advanced tablet manufacturing technology, equipped with a manufacturing management and quality control system compliant with GMP standards for pharmaceuticals and health foods.
● Shiga Factory:
The main production base for seamless capsules. Under strict manufacturing management and quality control compliant with US cGMP standards, it is responsible for manufacturing seamless capsules used in pharmaceuticals, health foods, food products, etc.
Company Name: Morishita Jintan Co., Ltd.
Representative: Yuji Morishita, Representative Director and President
Founded: February 1893 (Meiji 26)
Established: November 1936 (Showa 11)
Main Business: Manufacturing and sales of pharmaceuticals, quasi-drugs, medical devices, and food products.
URL: https://www.jintan.co.jp/
Founder Hiroshi Morishita, with a belief in "service to society," has provided products that contribute to people's health and rich lives since the company's founding in 1893. At that time, it developed as a comprehensive pocket health medicine (then Akadaitsubu Jintan), and later became the silver-coated "Jintan" (currently a quasi-drug, product name: Jintan N) familiar as a refreshing oral agent. Inspired by its manufacturing, it has uniquely developed and expanded its business domain with "seamless capsule technology," and through the accumulation of herbal medicine research and the establishment and cultivation of unique technologies, it conducts corporate activities in a wide range of fields.